Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.68 |
| ▸ | STS | P08842 | 5/20 | 0.65 |
| ▸ | ESR1 | P03372 | 9/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.64 |
| ▸ | AR | P10275 | 4/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.64 |
| ▸ | SNCA | P37840 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 3/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864592 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL29643366 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL172746 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL28373123 | 0.90 | SHBG (0.81) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL6695130 | 0.86 | SHBG (0.75) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL5143409 | 0.85 | SHBG (0.74) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL8606752 | 0.84 | SHBG (0.72) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL23027370 | 0.84 | SHBG (0.71) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL2232239 | 0.84 | STS (0.74) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL23645588 | 0.84 | STS (0.74) | SHBGHSD17B1STSESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2022-06-23 | — | — | US | claimed |
| CN-113473974-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2021-10-01 | — | — | CN | claimed |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2020-07-30 | — | — | US | claimed |
| WO-2014131891-A1 | USE OF FETUIN-B FOR CULTURE OF OOCYTES | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2014-09-04 | — | — | WO | claimed |
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | PHERIN PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | claimed |
| US-20090124587-A1 | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS | AUERBACH ALAN H | 2009-05-14 | — | — | US | claimed |
| WO-2009009132-A1 | USE OF 17ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITORS FOR THE TREATMENT OF CANCER | COUGAR BIOTECHNOLOGY, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| US-7078395-B1 | Methods for treating or preventing cancer by preventing, inhibiting or arresting cell cycling | STERIX LIMITED (GB) | 2006-07-18 | — | — | US | claimed |
| US-20060122161-A1 | Methods for treating or preventing cancer by preventing, inhibiting, or arresting cell cycling | STERIX LIMITED | 2006-06-08 | — | — | US | claimed |
| EP-1237902-B1 | HALOGENATED SULPHAMATE-, PHOSPHONATE-, THIOPHOSPHONATE-, SULPHONATE- AND SULPHONAMIDE- COMPOUNDS AS INHIBITORS OF STEROID SULPHATASE | STERIX LTD (GB) | 2005-11-02 | — | — | EP | claimed |
| EP-0633893-B1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BTG INT LTD (GB) | 1999-11-24 | — | — | EP | claimed |
| EP-0862577-B1 | SULPHAMATE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE DERIVATIVES, METHODS OF PRODUCING THEM AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM | JENAPHARM GMBH (DE) | 1999-04-14 | — | — | EP | claimed |
| EP-0891188-A1 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | Pherin Pharmaceuticals, Inc. (US) | 1999-01-20 | — | — | EP | claimed |
| JP-2742331-B2 | — | — | 1998-04-22 | — | — | JP | claimed |
| US-5705495-A | STEROIDS WITH ESTROGENIC EFFECT | JENAPHARM GMBH & CO. KG. (DE) | 1998-01-06 | — | — | US | claimed |
| EP-0715517-A1 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1996-06-12 | — | — | EP | claimed |
| CN-1101648-A | Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical | PHERIN CORP (US) | 1995-04-19 | — | — | CN | claimed |
| EP-0633893-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD (GB) | 1995-01-18 | — | — | EP | claimed |
| WO-1994028903-A1 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1994-12-22 | — | — | WO | claimed |
| WO-1993020097-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-10-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124587-A1 | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B11 | SHBG 94/4885HSD17B1 4/4885STS 118/4885 |
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | SHBG 1170/4885HSD17B1 418/4885STS 1437/4885 |
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | CYP19A1, SHBG, HSD17B11 | SHBG 2/4885HSD17B1 19/4885STS 209/4885 |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | SHBG 1170/4885HSD17B1 418/4885STS 1437/4885 |
| US-20060122161-A1 | Methods for treating or preventing cancer by preventing, inhibiting, or arresting cell cycling | CCAR2, CCNO, CCNY | SHBG 796/4885HSD17B1 130/4885STS 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.